165 related articles for article (PubMed ID: 14500395)
21. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
Akeno-Stuart N; Croyle M; Knauf JA; Malaguarnera R; Vitagliano D; Santoro M; Stephan C; Grosios K; Wartmann M; Cozens R; Caravatti G; Fabbro D; Lane HA; Fagin JA
Cancer Res; 2007 Jul; 67(14):6956-64. PubMed ID: 17638907
[TBL] [Abstract][Full Text] [Related]
22. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors.
Cohen MS; Hussain HB; Moley JF
Surgery; 2002 Dec; 132(6):960-6; discussion 966-7. PubMed ID: 12490842
[TBL] [Abstract][Full Text] [Related]
24. [Neural crest and multiple endocrinopathies].
Pasini A; Michiels FM; Chappuis-Flament S; Geneste O; Rossel M; Fournier L; Feunteun J; Lenoir G; Schuffenecker I; Billaud M
C R Seances Soc Biol Fil; 1996; 190(5-6):557-67. PubMed ID: 9074721
[TBL] [Abstract][Full Text] [Related]
25. Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
Frank-Raue K; Rondot S; Schulze E; Raue F
Clin Lab; 2007; 53(5-6):273-82. PubMed ID: 17605401
[TBL] [Abstract][Full Text] [Related]
26. Clinical manifestations of familial medullary thyroid carcinoma.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):348-50. PubMed ID: 15271414
[TBL] [Abstract][Full Text] [Related]
27. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic.
Jindrichová S; Vcelák J; Vlcek P; Neradilová M; Nemec J; Bendlová B
J Endocrinol; 2004 Nov; 183(2):257-65. PubMed ID: 15531714
[TBL] [Abstract][Full Text] [Related]
28. RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor.
Bongarzone I; Carniti C; Perego C; Mondellini P; Pierotti MA
Tumori; 2003; 89(5):550-2. PubMed ID: 14870784
[TBL] [Abstract][Full Text] [Related]
29. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
[TBL] [Abstract][Full Text] [Related]
30. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
[TBL] [Abstract][Full Text] [Related]
31. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
32. The RET proto-oncogene: a potential target for molecular cancer therapy.
Pützer BM; Drosten M
Trends Mol Med; 2004 Jul; 10(7):351-7. PubMed ID: 15242684
[TBL] [Abstract][Full Text] [Related]
33. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
Vitagliano D; De Falco V; Tamburrino A; Coluzzi S; Troncone G; Chiappetta G; Ciardiello F; Tortora G; Fagin JA; Ryan AJ; Carlomagno F; Santoro M
Endocr Relat Cancer; 2011 Feb; 18(1):1-11. PubMed ID: 20943719
[TBL] [Abstract][Full Text] [Related]
34. Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.
Carlomagno F; Santoro M
J Chemother; 2004 Nov; 16 Suppl 4():49-51. PubMed ID: 15693160
[TBL] [Abstract][Full Text] [Related]
35. A case of advanced medullary thyroid carcinoma successfully treated with sunitinib.
Bugalho MJ; Domingues R; Borges A
Oncologist; 2009 Nov; 14(11):1083-7. PubMed ID: 19887470
[TBL] [Abstract][Full Text] [Related]
36. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
Kumarasamy VM; Sun D
Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
[TBL] [Abstract][Full Text] [Related]
37. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
[No Abstract] [Full Text] [Related]
38. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
Hong D; Ye L; Gagel R; Chintala L; El Naggar AK; Wright J; Kurzrock R
Mol Cancer Ther; 2008 May; 7(5):1001-6. PubMed ID: 18445656
[TBL] [Abstract][Full Text] [Related]
39. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
[TBL] [Abstract][Full Text] [Related]
40. Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.
Broutin S; Ameur N; Lacroix L; Robert T; Petit B; Oumata N; Talbot M; Caillou B; Schlumberger M; Dupuy C; Bidart JM
Clin Cancer Res; 2011 Apr; 17(7):2044-54. PubMed ID: 21325074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
